1. Home
  2. ASRT vs QNCX Comparison

ASRT vs QNCX Comparison

Compare ASRT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASRT
  • QNCX
  • Stock Information
  • Founded
  • ASRT 1995
  • QNCX 2012
  • Country
  • ASRT United States
  • QNCX United States
  • Employees
  • ASRT N/A
  • QNCX N/A
  • Industry
  • ASRT Biotechnology: Pharmaceutical Preparations
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ASRT Health Care
  • QNCX Health Care
  • Exchange
  • ASRT Nasdaq
  • QNCX Nasdaq
  • Market Cap
  • ASRT 85.1M
  • QNCX 70.4M
  • IPO Year
  • ASRT 1997
  • QNCX 2019
  • Fundamental
  • Price
  • ASRT $0.80
  • QNCX $1.60
  • Analyst Decision
  • ASRT Strong Buy
  • QNCX Strong Buy
  • Analyst Count
  • ASRT 4
  • QNCX 4
  • Target Price
  • ASRT $3.19
  • QNCX $9.50
  • AVG Volume (30 Days)
  • ASRT 357.9K
  • QNCX 143.6K
  • Earning Date
  • ASRT 03-10-2025
  • QNCX 03-31-2025
  • Dividend Yield
  • ASRT N/A
  • QNCX N/A
  • EPS Growth
  • ASRT N/A
  • QNCX N/A
  • EPS
  • ASRT N/A
  • QNCX N/A
  • Revenue
  • ASRT $125,763,000.00
  • QNCX N/A
  • Revenue This Year
  • ASRT N/A
  • QNCX N/A
  • Revenue Next Year
  • ASRT $1.84
  • QNCX N/A
  • P/E Ratio
  • ASRT N/A
  • QNCX N/A
  • Revenue Growth
  • ASRT N/A
  • QNCX N/A
  • 52 Week Low
  • ASRT $0.73
  • QNCX $0.51
  • 52 Week High
  • ASRT $1.80
  • QNCX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • ASRT 43.92
  • QNCX 43.92
  • Support Level
  • ASRT $0.78
  • QNCX $1.49
  • Resistance Level
  • ASRT $0.83
  • QNCX $1.69
  • Average True Range (ATR)
  • ASRT 0.03
  • QNCX 0.14
  • MACD
  • ASRT 0.00
  • QNCX 0.00
  • Stochastic Oscillator
  • ASRT 39.86
  • QNCX 46.15

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.

Share on Social Networks: